Maxime Dely: Why Centrifugation is the “Invisible Core” and Critical Lever in Blood Component Processing
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post onย LinkedIn:
“Centrifugation: the invisible core of blood component processing laboratories
In Processing laboratories, centrifuges are often perceived as standard equipment โ reliable, essential, almost routine.
In practice, however, centrifugation isย a major physico-technical lever of the overall blood component valorization process, directly impacting product quality, yields and reproducibility ๐ฝ๐ฟ๐ผ๐ฑ๐๐ฐ๐
๐๐ถ๐ฟ๐๐ ๐ฐ๐ต๐ฎ๐น๐น๐ฒ๐ป๐ด๐ฒ: ๐๐ถ๐บ๐ฒ ๐ผ๐ฝ๐๐ถ๐บ๐ถ๐๐ฎ๐๐ถ๐ผ๐ป
Under increasing pressure to reduce turnaround times, processing laboratories strive to shorten processing durations while ensuring quality and compliance. Centrifugation sequences โ through their duration, capacity, sequencing, and transient phases โ can quickly become aย ๐ฐ๐ฟ๐ถ๐๐ถ๐ฐ๐ฎ๐น ๐ฏ๐ผ๐๐๐น๐ฒ๐ป๐ฒ๐ฐ๐ธย if they are not carefully integrated into the global workflow.
๐ฆ๐ฒ๐ฐ๐ผ๐ป๐ฑ ๐ฐ๐ต๐ฎ๐น๐น๐ฒ๐ป๐ด๐ฒ: ๐๐ต๐ฒ โ๐ฏ๐น๐ฎ๐ฐ๐ธ ๐ฏ๐ผ๐ โ ๐ฒ๐ณ๐ณ๐ฒ๐ฐ๐
For many laboratories, centrifugation remains insufficiently characterized. Yet separation mechanisms and cellular and plasma yields are directly influenced by key parameters:
- ย Acceleration and deceleration profiles (shear stress, resuspension effects)
- ย Effective centrifugation time at constant g
- ย Rotor radius and bucket geometry, shaping force gradients
- ย Applied g-forces and stability of plasma/cell interfaces
- ย Bag positioning, processed volumes, and balancing conditions
This parameter complexity explains whyย ๐๐ถ๐บ๐ฝ๐น๐ฒ ๐ฝ๐ฟ๐ผ๐๐ผ๐ฐ๐ผ๐น ๐ฐ๐ผ๐ฝ๐-๐ฝ๐ฎ๐๐๐ฒ ๐ฏ๐ฒ๐๐๐ฒ๐ฒ๐ป ๐น๐ฎ๐ฏ๐ผ๐ฟ๐ฎ๐๐ผ๐ฟ๐ถ๐ฒ๐ ๐ฑ๐ผ๐ฒ๐ ๐ป๐ผ๐ ๐๐ผ๐ฟ๐ธ. Even under nominally identical conditions, result variability remains significant.
Centrifugation is therefore not just about โplacing bags into buckets and pressing playโ.
It deserves a more analytical approach, grounded in physical understanding and experimentation, toย ๐ฏ๐ฒ๐๐๐ฒ๐ฟ ๐ฐ๐ผ๐ป๐๐ฟ๐ผ๐น ๐ฐ๐๐ฟ๐ฟ๐ฒ๐ป๐ ๐ฝ๐ฟ๐ผ๐ฐ๐ฒ๐๐๐ฒ๐ ๐ฎ๐ป๐ฑ ๐ฑ๐ฒ๐๐ถ๐ด๐ป ๐๐ต๐ฒ ๐ป๐ฒ๐ ๐ ๐ด๐ฒ๐ป๐ฒ๐ฟ๐ฎ๐๐ถ๐ผ๐ป ๐ผ๐ณ ๐๐ผ๐ฟ๐ธ๐ณ๐น๐ผ๐๐.
Overall performance is often determined by the parameters we tend to overlook.”
Find more posts featuringย Maxime Dely on Hemostasis Today.
-
Feb 20, 2026, 13:45Danny Hsu: Can We Prevent VTE Without Increasing Bleeding Risk?
-
Feb 20, 2026, 10:26Eithne Sexton: Our Interactive Dashboards for Future Stroke Projections at SPHeRE Conference
-
Feb 20, 2026, 10:06Rรฉmi Bonjean: The 1st VHHs Against Active Rap1 to Monitor Platelet Activation
-
Feb 20, 2026, 09:50Latifa Alhassan: HIV Is a Danger Looming For Our Unborn Children and For The Economy of Ghana
-
Feb 20, 2026, 09:35Gregory Makris: Factor XI Makes the Leap from OCEANIC Stroke to the ESO 2025 Update
-
Feb 20, 2026, 09:27Waseem Mujahed: Compartment Syndrome as the Initial Presentation of Postpartum Acquired Hemophilia
-
Feb 20, 2026, 09:21Piotr Czempik: Viscoelastic Testing Guiding Lumbar Puncture in Waldenstrรถmโs Macroglobulinemia
-
Feb 20, 2026, 09:14Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH
-
Feb 20, 2026, 09:04Rens De Groot: The 1st Reported Case of Caplacizumab Resistance